These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

354 related articles for article (PubMed ID: 28196522)

  • 1. XPO1 in B cell hematological malignancies: from recurrent somatic mutations to targeted therapy.
    Camus V; Miloudi H; Taly A; Sola B; Jardin F
    J Hematol Oncol; 2017 Feb; 10(1):47. PubMed ID: 28196522
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recurrent mutations of the exportin 1 gene (XPO1) and their impact on selective inhibitor of nuclear export compounds sensitivity in primary mediastinal B-cell lymphoma.
    Jardin F; Pujals A; Pelletier L; Bohers E; Camus V; Mareschal S; Dubois S; Sola B; Ochmann M; Lemonnier F; Viailly PJ; Bertrand P; Maingonnat C; Traverse-Glehen A; Gaulard P; Damotte D; Delarue R; Haioun C; Argueta C; Landesman Y; Salles G; Jais JP; Figeac M; Copie-Bergman C; Molina TJ; Picquenot JM; Cornic M; Fest T; Milpied N; Lemasle E; Stamatoullas A; Moeller P; Dyer MJ; Sundstrom C; Bastard C; Tilly H; Leroy K
    Am J Hematol; 2016 Sep; 91(9):923-30. PubMed ID: 27312795
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detection and prognostic value of recurrent exportin 1 mutations in tumor and cell-free circulating DNA of patients with classical Hodgkin lymphoma.
    Camus V; Stamatoullas A; Mareschal S; Viailly PJ; Sarafan-Vasseur N; Bohers E; Dubois S; Picquenot JM; Ruminy P; Maingonnat C; Bertrand P; Cornic M; Tallon-Simon V; Becker S; Veresezan L; Frebourg T; Vera P; Bastard C; Tilly H; Jardin F
    Haematologica; 2016 Sep; 101(9):1094-101. PubMed ID: 27479820
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The nuclear export protein XPO1 - from biology to targeted therapy.
    Azmi AS; Uddin MH; Mohammad RM
    Nat Rev Clin Oncol; 2021 Mar; 18(3):152-169. PubMed ID: 33173198
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A first-in-class inhibitor of HSP110 to potentiate XPO1-targeted therapy in primary mediastinal B-cell lymphoma and classical Hodgkin lymphoma.
    Durand M; Cabaud Gibouin V; Duplomb L; Salmi L; Caillot M; Sola B; Camus V; Jardin F; Garrido C; Jego G
    J Exp Clin Cancer Res; 2024 May; 43(1):148. PubMed ID: 38773631
    [TBL] [Abstract][Full Text] [Related]  

  • 6. STAT6 is a cargo of exportin 1: Biological relevance in primary mediastinal B-cell lymphoma.
    Miloudi H; Leroy K; Jardin F; Sola B
    Cell Signal; 2018 Jun; 46():76-82. PubMed ID: 29501729
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recurrent XPO1 mutations alter pathogenesis of chronic lymphocytic leukemia.
    Walker JS; Hing ZA; Harrington B; Baumhardt J; Ozer HG; Lehman A; Giacopelli B; Beaver L; Williams K; Skinner JN; Cempre CB; Sun Q; Shacham S; Stromberg BR; Summers MK; Abruzzo LV; Rassenti L; Kipps TJ; Parikh S; Kay NE; Rogers KA; Woyach JA; Coppola V; Chook YM; Oakes C; Byrd JC; Lapalombella R
    J Hematol Oncol; 2021 Jan; 14(1):17. PubMed ID: 33451349
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protein biomarkers for response to XPO1 inhibition in haematologic malignancies.
    Totiger TM; Chaudhry S; Musi E; Afaghani J; Montoya S; Owusu-Ansah F; Lee S; Schwartz G; Klimek V; Taylor J
    J Cell Mol Med; 2023 Feb; 27(4):587-590. PubMed ID: 36722323
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Digital PCR for quantification of recurrent and potentially actionable somatic mutations in circulating free DNA from patients with diffuse large B-cell lymphoma.
    Camus V; Sarafan-Vasseur N; Bohers E; Dubois S; Mareschal S; Bertrand P; Viailly PJ; Ruminy P; Maingonnat C; Lemasle E; Stamatoullas A; Picquenot JM; Cornic M; Beaussire L; Bastard C; Frebourg T; Tilly H; Jardin F
    Leuk Lymphoma; 2016 Sep; 57(9):2171-9. PubMed ID: 26883583
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Next-generation XPO1 inhibitor shows improved efficacy and in vivo tolerability in hematological malignancies.
    Hing ZA; Fung HY; Ranganathan P; Mitchell S; El-Gamal D; Woyach JA; Williams K; Goettl VM; Smith J; Yu X; Meng X; Sun Q; Cagatay T; Lehman AM; Lucas DM; Baloglu E; Shacham S; Kauffman MG; Byrd JC; Chook YM; Garzon R; Lapalombella R
    Leukemia; 2016 Dec; 30(12):2364-2372. PubMed ID: 27323910
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exportin 1-mediated nuclear/cytoplasmic trafficking controls drug sensitivity of classical Hodgkin's lymphoma.
    Caillot M; Miloudi H; Taly A; Profitós-Pelejà N; Santos JC; Ribeiro ML; Maitre E; Saule S; Roué G; Jardin F; Sola B
    Mol Oncol; 2023 Dec; 17(12):2546-2564. PubMed ID: 36727672
    [TBL] [Abstract][Full Text] [Related]  

  • 12. EBV-Positive Primary Large B-Cell Lymphoma: The Role of Immunohistochemistry and XPO1 in the Diagnosis of Mediastinal Lymphomas.
    Maracaja DLV; Puthenpura V; Pels SG; O'Malley DP; Sklar JL; Finberg KE; Xu ML
    Appl Immunohistochem Mol Morphol; 2020; 28(10):725-730. PubMed ID: 31789821
    [TBL] [Abstract][Full Text] [Related]  

  • 13.
    Miloudi H; Bohers É; Guillonneau F; Taly A; Gibouin VC; Viailly PJ; Jego G; Grumolato L; Jardin F; Sola B
    Cancers (Basel); 2020 Sep; 12(10):. PubMed ID: 33007990
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genome-wide studies in multiple myeloma identify XPO1/CRM1 as a critical target validated using the selective nuclear export inhibitor KPT-276.
    Schmidt J; Braggio E; Kortuem KM; Egan JB; Zhu YX; Xin CS; Tiedemann RE; Palmer SE; Garbitt VM; McCauley D; Kauffman M; Shacham S; Chesi M; Bergsagel PL; Stewart AK
    Leukemia; 2013 Dec; 27(12):2357-65. PubMed ID: 23752175
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ribosomal Biogenesis and Translational Flux Inhibition by the Selective Inhibitor of Nuclear Export (SINE) XPO1 Antagonist KPT-185.
    Tabe Y; Kojima K; Yamamoto S; Sekihara K; Matsushita H; Davis RE; Wang Z; Ma W; Ishizawa J; Kazuno S; Kauffman M; Shacham S; Fujimura T; Ueno T; Miida T; Andreeff M
    PLoS One; 2015; 10(9):e0137210. PubMed ID: 26340096
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Altered Nuclear Export Signal Recognition as a Driver of Oncogenesis.
    Taylor J; Sendino M; Gorelick AN; Pastore A; Chang MT; Penson AV; Gavrila EI; Stewart C; Melnik EM; Herrejon Chavez F; Bitner L; Yoshimi A; Lee SC; Inoue D; Liu B; Zhang XJ; Mato AR; Dogan A; Kharas MG; Chen Y; Wang D; Soni RK; Hendrickson RC; Prieto G; Rodriguez JA; Taylor BS; Abdel-Wahab O
    Cancer Discov; 2019 Oct; 9(10):1452-1467. PubMed ID: 31285298
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Heterozygous mutation of cysteine528 in XPO1 is sufficient for resistance to selective inhibitors of nuclear export.
    Neggers JE; Vanstreels E; Baloglu E; Shacham S; Landesman Y; Daelemans D
    Oncotarget; 2016 Oct; 7(42):68842-68850. PubMed ID: 27634897
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Second-Generation Exportin-1 Inhibitor KPT-8602 Demonstrates Potent Activity against Acute Lymphoblastic Leukemia.
    Vercruysse T; De Bie J; Neggers JE; Jacquemyn M; Vanstreels E; Schmid-Burgk JL; Hornung V; Baloglu E; Landesman Y; Senapedis W; Shacham S; Dagklis A; Cools J; Daelemans D
    Clin Cancer Res; 2017 May; 23(10):2528-2541. PubMed ID: 27780859
    [No Abstract]   [Full Text] [Related]  

  • 19. Selinexor, selective inhibitor of nuclear export: Unselective bullet for blood cancers.
    Benkova K; Mihalyova J; Hajek R; Jelinek T
    Blood Rev; 2021 Mar; 46():100758. PubMed ID: 32972802
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human Exportin-1 is a Target for Combined Therapy of HIV and AIDS Related Lymphoma.
    Boons E; Vanstreels E; Jacquemyn M; Nogueira TC; Neggers JE; Vercruysse T; van den Oord J; Tamir S; Shacham S; Landesman Y; Snoeck R; Pannecouque C; Andrei G; Daelemans D
    EBioMedicine; 2015 Sep; 2(9):1102-13. PubMed ID: 26501108
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.